vs
ASP Isotopes Inc.（ASPI）与Xilio Therapeutics, Inc.（XLO）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Xilio Therapeutics, Inc.的1.2倍（$16.7M vs $13.7M），Xilio Therapeutics, Inc.自由现金流更多（$-2.1M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Xilio Therapeutics是一家临床阶段生物技术企业，专注开发用于多种癌症治疗的新型肿瘤选择性免疫疗法，其在研候选药物可在肿瘤微环境中特异性激活抗肿瘤免疫反应，降低全身性毒副作用，主要面向北美及全球其他地区的肿瘤患者群体。
ASPI vs XLO — 直观对比
营收规模更大
ASPI
是对方的1.2倍
$13.7M
自由现金流更多
XLO
多$45.3M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $13.7M |
| 净利润 | — | $10.4M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -86.5% |
| 净利率 | — | 75.7% |
| 营收同比 | 1295.7% | — |
| 净利润同比 | -586.8% | 179.1% |
| 每股收益（稀释后） | — | $-3.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIXLO
| Q4 25 | $16.7M | $13.7M | ||
| Q3 25 | $4.9M | $19.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $2.9M |
净利润ASPIXLO
| Q4 25 | — | $10.4M | ||
| Q3 25 | $-12.9M | $-16.3M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-13.3M |
毛利率ASPIXLO
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
营业利润率ASPIXLO
| Q4 25 | — | -86.5% | ||
| Q3 25 | -306.1% | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | — | -472.7% |
净利率ASPIXLO
| Q4 25 | — | 75.7% | ||
| Q3 25 | -263.7% | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | — | -452.7% |
每股收益（稀释后）ASPIXLO
| Q4 25 | — | $-3.74 | ||
| Q3 25 | $-0.15 | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $137.5M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $35.3M |
| 总资产 | $498.0M | $154.7M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIXLO
| Q4 25 | $333.3M | $137.5M | ||
| Q3 25 | $113.9M | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M |
总债务ASPIXLO
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
股东权益ASPIXLO
| Q4 25 | $204.2M | $35.3M | ||
| Q3 25 | $74.1M | $-8.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | — | $10.7M |
总资产ASPIXLO
| Q4 25 | $498.0M | $154.7M | ||
| Q3 25 | $225.9M | $133.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | — | $103.7M |
负债/权益比ASPIXLO
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-2.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-2.1M |
| 自由现金流率自由现金流/营收 | -284.7% | -15.3% |
| 资本支出强度资本支出/营收 | 57.9% | 0.7% |
| 现金转化率经营现金流/净利润 | — | -0.19× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIXLO
| Q4 25 | $-37.8M | $-2.0M | ||
| Q3 25 | $-8.9M | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $29.0M |
自由现金流ASPIXLO
| Q4 25 | $-47.4M | $-2.1M | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M |
自由现金流率ASPIXLO
| Q4 25 | -284.7% | -15.3% | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% |
资本支出强度ASPIXLO
| Q4 25 | 57.9% | 0.7% | ||
| Q3 25 | 64.4% | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% |
现金转化率ASPIXLO
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
